Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

1 evidence topic · 2 sources

Constitutional and pain symptoms in the exon 20 insertion population

“One conference abstract described the symptom burden for Exon 20ins patients with fatigue and pain being most common.” (opens the source at this quote in a new tab)